Merck & Company Inc (MRK)vsTscan Therapeutics Inc (TCRX)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
TCRX
Tscan Therapeutics Inc
$1.15
-8.73%
HEALTHCARE · Cap: $75.73M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 629546% more annual revenue ($65.01B vs $10.32M). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
TCRX
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
-23.1%
Fair Value
$0.79
Current Price
$1.15
$0.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Revenue surging 286.0% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -71.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : TCRX
The strongest argument for TCRX centers on Price/Book, Revenue Growth. Revenue growth of 286.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : TCRX
The primary concerns for TCRX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while TCRX is a hypergrowth play — different risk/reward profiles.
TCRX carries more volatility with a beta of 1.01 — expect wider price swings.
TCRX is growing revenue faster at 286.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 40/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Tscan Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology company committed to revolutionizing cancer treatment through its advanced T cell receptor (TCR) discovery platform, which targets specific cancer antigens for precision immunotherapy solutions. The firm’s innovative approach aims to translate cutting-edge scientific research into effective TCR-based therapeutics, enhancing treatment options for a variety of malignancies. With a robust pipeline and a solid intellectual property portfolio, Tscan Therapeutics is strategically positioned to become a key player in the fast-growing sector of T cell-based cancer therapies, addressing significant unmet medical needs and improving patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?